Philadelphia Hepatitis B & Hepatitis C Elimination Plan

HIV Integrated Planning Council

January 12, 2023



Background

Department of Health & Human Services Viral Hepatitis National Strategic Plan

- A Roadmap to Elimination (2021 2025)
- COMBATING THE SILENT EPIDEMIC of VIRAL
 HEPATITIS Action Plan for the Prevention, Care
 & Treatment of Viral Hepatitis (2011 2013)
- Action Plan for the Prevention, Care, &
 Treatment of Viral Hepatitis (2014 2016)
- National Viral Hepatitis Action Plan 2017-2020





COMBATING THE SILENT EI
OF VIRAL HEPATITIS

Action Plan for the Prevention, Care & Treatm of Viral Hepatitis

National Strategic Plan
A Roadmap to Elimination

for the United States | 2021-2025



Pennsylvania Viral Hepatitis Elimination Plan

Bureau of Epidemiology

March 2022

Michigan's
State Plan on
Eliminating
Hepatitis C










Michigan Department of Health + Human Services | 2021




WORLD HEPATITIS DAY | JULY 28

Eliminate Viral Hepatitis

Plan to

as a Major Public Health Threat in New York City by 2030



New York City Department of Health and Mental Hygiene

Hepatitis C Elimination Plan






HEP FREE 2030:
THE HAWAI'I
HEPATITIS
ELIMINATION
STRATEGY
2020-2030







World Health Organization(WHO) Goals Elimination of Hepatitis B & Hepatitis C

Target Area	2015 Baseline	2020 Target	2030 Target
Hep B & C Incidence		30% reduction	90% reduction
Mortality from Hep B & C		10% reduction	65% reduction
Childhood HBV vaccination coverage	82%	90%	90%
Prevention of perinatal HBV transmission (birth dose & PEP)	38%	50%	90%
Blood safety (screening blood donations)		95%	100%
Safe injection & harm reduction (needles/PWID/yr)	20	200	300
Hep B & C diagnoses	<5%	30%	90%
Hep B & C treatment	<1%		80% treated

VIRAL HEPATITIS

National Strategic Plan A Roadmap to Elimination

for the United States | 2021-2025



B. Goals

In pursuit of this vision, the Hepatitis Plan establishes five goals:



1. Prevent new viral hepatitis infections



2. Improve viral hepatitis—related health outcomes of people with viral hepatitis



3. Reduce viral hepatitis-related disparities and health inequities



4. Improve viral hepatitis surveillance and data usage



5. Achieve integrated, coordinated efforts that address the viral hepatitis epidemics among all partners and stakeholders

VIRAL HEPATITIS

National Strategic Plan A Roadmap to Elimination

for the United States | 2021-2025



Table 3. Priority Populations by Hepatitis Type and Measure

	Incidence (Acute)	Prevalence (Chronic)	Mortality
Hepatitis A	 People who use drugs People experiencing homelessness 	Not Applicable	
Hepatitis B	People who inject drugs	 Asian and Pacific Islander Black, non-Hispanic 	 Asian and Pacific Islander Black, non-Hispanic
Hepatitis C	People who inject drugs American Indian/ Alaska Native	 People who inject drugs Black, non-Hispanic People born 1945-1965 People with HIV 	 American Indian/ Alaska Native Black, non-Hispanic People born 1945- 1965

Basic Viral Hepatitis Overview

Viral Hepatitis Infections

Hepatitis Type:	Α	В	С	D
Transmission	Fecal-Oral	Blood, semen, vaginal fluids	Blood, semen	Blood, semen, vaginal fluids; Must have Hep B present
Vaccine	Yes	Yes	No	No, but HBV vaccine protects
Acute-only	100%	90% of infants; 50% of young children; 5% of adults	25% of adults	No
Treatment	Supportive	Supportive and to reduce liver damage	Supportive and CURE	Supportive and to reduce liver damage

Hepatitis B and C Testing Recommendations

Hepatitis C

- One time screening for all people 18 years and older once in a lifetime.
- Continued testing for those at risk
- Screen people during each pregnancy

Hepatitis B

- In Q1 2023 will be a universal screening recommendation for adults
- Continued testing for those at risk
- Screen people during each pregnancy

Hepatitis B & Hepatitis C Context

Hepatitis B

Tools

- Effective vaccine! Universally recommended!
- Effective treatment can extend life expectancy
- Screening tests are widely available and billable

Challenges

- Highly transmissible
- Few symptoms for much of the disease
- Community bias/knowledge
- Need blood draw for diagnosis and treatment
- Vaccine hesitancy and other barriers amongst adults
- Cost to patient
- Many people got when were young children in other countries
- Provider education around screening/disease
- Chronic disease → long term engagement in care can fall off
- No cure

Hepatitis C


Tools

- There is a CURE! (And it is highly tolerable, 8-12 weeks, and all oral, w/ minimal side effects)
- Many providers can treat
- Universal screening recommendations
- Point-of-care screening test available
- Laboratory tests are widely available and billable

Challenges


- Highly transmissible
- Community bias/knowledge
- Need blood draw for diagnosis and treatment
- Prior Authorization process required for Medicaid patients
- Limited access to SSPs
- Many people in key communities aren't motivated to be cured
- Linkage to care after diagnosis falls off

Micro Elimination Success



C-YA!: Elimination of HCV among HIV/HCV Coinfected Individuals (2016-2019)

3,086 people coinfected with HIV/HCV in Philadelphia in 2016 (16% of HIV and 7% of HCV)



HRSA-Funded SPNS Project 2016 – 2019

- 1. Build capacity to test and treat HCV among HIV care providers
- 2. Prioritize HCV among HIV providers > EMR changes, TA meetings

C Ya Interventions: Increased HCV Testing and Treatment Capacity

Encouraged to standardize HCV reflex testing (HCV antibody with reflex testing to HCV RNA)

 \circ 2016: **9** sites (43%) \rightarrow 2019: **19** sites (90%)

Incorporate HCV treatment into HIV care : all sites have ≥1 HCV treater

• 14 sites in 2016 to 21 sites in 2019 and trained 89 providers

Identify Coinfected PLWH who are Out of HIV Care

• Leverage existing data-to-care infrastructure to relink PLWH to care → Use DIS


Address Co-occurring Outbreak of HIV among PWUD

Increased need to consider HIV among PWUD, improve PrEP prescriptions, and inform the community

HCV Care Continuum Improved

PLWH & HCV Diagnosis

- Baseline (Dec 31, 2016)
- Sept 30, 2019
- Sept 30, 2019 (Includes new HIV/HCV diagnosis)



Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office & Viral Hepatitis Program

Philly Planning



Considerations

- Philly is unique (and gritty).
- No funds promised for elimination activities
- Rich history of hepatitis elimination efforts
- Technical advisory team needed
- Digestible for general public
- Hepatitis doesn't exist in a vacuum
- PA DOH published Hepatitis A, B, & C Elimination Plan February 2022

Tentative Timeline

Planning Phase	Anticipated Dates
Active Community Engagement Outreach	December 2022 (paused)
Annual Report Release	Winter 2023
Final Plan Release	Winter2023
Implementation	2023 - 2030
Ongoing Community Feedback/Engagement	2023-2030
Annual Report and Progress Report	Annually 2023-2030

^{*} The Plan will be modified as needed to accommodate changing hepatitis landscape, such as medical advancements, clinical recommendations, and funding.

Hepatitis B & Hepatitis C Pillars

Education & Prevention

Testing & Linkage to Care

Care Engagement & Treatment

Data & Surveillance

Strategies


Health Equity Framework
Harm Reduction
Social Justice
HAV/HDV – as applicable
Cancer Prevention
Tool for Social Change

Viral Hepatitis Elimination Partner Feedback and Information

Goal: This is not a Viral Hepatitis Program Plan→ this is a PDPH, City, communities, CBO, & Philadelphia-wide Plan

Partners To Date

- Viral Hepatitis experts, advocates, & community members
- PDPH Programs
- Various City agencies
- Local viral hepatitis coalitions
- Community Engagement through various health outreach events including MPX clinics
- Virtual form & printed form



Viral Hepatitis Program | 1101 Market St. 12th Floor | Philadelphia, PA 19107

Thank you for your participation; your input is vital to developing a successful, sustainable Hepatitis B and C Elimination

Plan. For additional information on viral hepatitis or the Elimination Plan, go to Phillyhepatitis.org or phila.org/health

Community of Eliminators

Hepatitis C Allies of Philadelphia (HepCAP)

 City wide collective dedicated to improving the continuum of hepatitis C prevention, diagnosis, care, and support services with the goal of eliminating hepatitis C from Philadelphia

Hep B United Philadelphia (HBU)


 Local community-owned coalition that was created to increase hepatitis B testing and vaccination in Philadelphia through public awareness and education

Community Advisory Board (CAB)

 Group of people representing community groups and organizations, along with clinical staff, who share resources, troubleshoot, and collaborate to improve hepatitis B services in the Philadelphia area.


Community of Eliminators

- Viral Hepatitis Elimination Technical Advisory Committee (VHETAC)
 - Planning & Implementation
- Monthly Newsletter
 - Stay up-to-date with the latest Philly hep Happenings & other resources





- Hepatitis B and C Educational Materials
 - HEP has free print materials (French, Spanish, Vietnamese, Simplified Chinese)
 - Email w/ any hep-related questions hep-ddc@phila.gov
 - Hepcap.org & phillyhepatitis.org



Feedback & Questions

Melissa Hobkirk
Melissa.Hobkirk@phila.gov

Danica Kuncio@phila.gov

